Literature DB >> 16564936

Tissue Doppler imaging in the evaluation of left ventricular function in young adults with autosomal dominant polycystic kidney disease.

Edgar A F de Almeida1, Eduardo I de Oliveira, José A Lopes, Ana G Almeida, M Martins Prata.   

Abstract

BACKGROUND: Hypertension and increased left ventricular mass index (LVMI) have been reported in patients with early stages of autosomal dominant polycystic kidney disease (ADPKD). Whether these abnormalities are associated with diastolic dysfunction in this stage remains to be established. The aim of the study is to evaluate diastolic function in young normotensive patients with ADPKD by using tissue Doppler imaging (TDI), the most sensitive method available to date.
METHODS: Thirty-two young clinically normotensive patients aged 21 to 30 years were compared with 23 controls with similar ages. Ambulatory blood pressure measurement (ABPM) was performed to confirm normal blood pressure. Subsequently, patients and controls underwent echocardiography using transmitral Doppler and TDI.
RESULTS: LVMI was greater in patients with ADPKD than controls (89.3 +/- 17.7 versus 77.6 +/- 15.9 g/m2; P < 0.02). No significant differences were found in transmitral Doppler and TDI results. When ABPMs were taken into account, 11 patients had mild hypertension and showed increased LVMI and decreased early diastolic peak velocity (E wave: 67.0 +/- 12.0 cm/s in hypertensive patients with ADPKD versus 81.4 +/- 3.3 cm/s in normotensive patients with ADPKD versus 79.3 +/- 2.9 cm/s in controls; P < 0.04) and decreased TDI peak early diastolic annular velocity (11.6 +/- 2.8 cm/s in hypertensive patients with ADPKD versus 13.2 +/- 1.6 cm/s in normotensive patients with ADPKD versus 13.4 +/- 1.6 in controls; P < 0.05).
CONCLUSION: Diastolic dysfunction is not a prominent sign in young normotensive patients with ADPKD.

Entities:  

Mesh:

Year:  2006        PMID: 16564936     DOI: 10.1053/j.ajkd.2005.12.023

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  5 in total

1.  Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease.

Authors:  Miklos Z Molnar; Lilia R Lukowsky; Elani Streja; Ramanath Dukkipati; Jennie Jing; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Hypertens       Date:  2010-12       Impact factor: 4.844

Review 2.  Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Authors:  Tevfik Ecder; Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

3.  Morning blood pressure surge in early autosomal dominant polycystic kidney disease and its relation with left ventricular hypertrophy.

Authors:  Abdülmecit Yildiz; Saim Sag; Cuma Bulent Gul; Sümeyye Güllülü; Fatma Ezgi Can; Ömer Bedir; Mehmet Fethullah Aydin; Ayşegül Oruç; Sadettin Demirel; Suat Akgür; Mustafa Güllülü; Alparslan Ersoy
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

4.  Establishing a core outcome measure for pain in patients with autosomal dominant polycystic kidney disease: a consensus workshop report.

Authors:  Patrizia Natale; Ronald D Perrone; Allison Tong; Tess Harris; Elyssa Hannan; Angela Ju; Eva Burnette; Niek F Casteleijn; Arlene Chapman; Sarah Eastty; Ron T Gansevoort; Marie Hogan; Shigeo Horie; Bertrand Knebelmann; Richard Lee; Reem A Mustafa; Richard Sandford; Amanda Baumgart; Jonathan C Craig; Gopala K Rangan; Bénédicte Sautenet; Andrea K Viecelli; Noa Amir; Nicole Evangelidis; Chandana Guha; Charlotte Logeman; Karine Manera; Andrea Matus Gonzalez; Martin Howell; Giovanni F M Strippoli; Yeoungjee Cho
Journal:  Clin Kidney J       Date:  2021-07-06

5.  Characterisation of left ventricular function by tissue Doppler imaging technique in newly diagnosed, untreated hypertensive subjects.

Authors:  Adedeji K Adebayo; Olulola O Oladapo; Adewole A Adebiyi; Olayinka O Ogunleye; Okechukwu S Ogah; Dike B Ojji; Moshood A Adeoye; Kenneth C Ochulor; Evbu O Enakpene; Ayodele O Falase
Journal:  Cardiovasc J Afr       Date:  2008 Sep-Oct       Impact factor: 1.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.